ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2991

Evaluation of Serum Levels of Adipokines and Interleukines in Pericardial Effusion Related to Systemic Sclerosis

Angela Chialà1, Cinzia Rotondo1, Maria Grazia Anelli1, Emanuela Praino1, Luca Cantarini2, Crescenzio Scioscia1, Margherita Giannini1, Giovanni Lapadula1 and Florenzo Iannone1, 1DIM, Rheumatology Unit, Bari, Italy, 2Univ Siena, Siena, Italy

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Adipokines, Heart disease, interleukins (IL) and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Pericardial involvement is common in rheumatic disease, as rheumatoid arthritis, lupus erythematosus, mixed connective disease and systemic sclerosis. Few data are available about pathogenesis of pericardial effusion in systemic sclerosis. This study aimed at evaluating the differences in serum levels of adipokines and interleukins (IL) in systemic sclerosis (SSc) patients with and without pericardial effusion.

Methods: A total of 87 outpatients (84 female, mean age of 52,6±14,2 ys, and disease duration of 8,2±6,7 ys), who fulfilled  the ACR/EULAR 2013 SSc classification criteria, were recruited in this study. The anthropometric measures, as body mass index (BMI), demographic, clinical and laboratoristic characteristics and SSc related manifestations were assessed in each patient. The presence of pericardial effusion (PE) was evaluated by means of echocardiographic techniques (the presence of fluid ≥ 5 cc was considered pathologic). Sera levels of adiponectin, leptin, resistin, visfatin, tumor necrosis factor α (TNF-α), interferon g (INF-g), IL-2, IL-10 and IL-17 were measured in SSc patients, using Multiplex Immunoassay (Bioplex 200 System), by means of two kits (Bioplex ProTM Cytokine/Chemokine and Growth Factor Assay e Bioplex Pro Diabetes Assay). The data normality was verified using Kolmogorov-Smirnov Test; the comparisons between SSc patients groups  were evaluated by Mann-Whitney U test and t-student test, where appropiate. Statistic significance was set at p≤0,05. The results are expressed as median and interquartile range (IQR) or means±1standard deviation. The data analysis were assessed using IBM SPSS statistic 20.

Results: 11 SSc patients had pericardial effusion (PE). The SSc patients groups (with and without PE) did not differ in age (46,5±13,8 ys vs 53,5±14,2 ys), sex and BMI (24,4±5,5 vs 23,62±4,12). 11 SSc patients were obese (BMI≥30) (2 with PE and 9 without PE). We observed significant differences between SSc patients with PE and without PE in sera levels of visfatin (1546,9 (8590,9) vs 388,8 (103); p=0,036), adiponectin (2845000 (4132900,0) vs 5272100,0 (8243600,0); p=0,027) and IL-17 (1,33 (3,5) vs 0,05 (0,56); p=0,45). Moreover higher leptin/adiponectin ratio was found in patients with PE (0,006 (0,01) vs 0,0017 (0,00); p= 0,032). The sera levels of adipokines and IL did not change in SSc patients with interstitial lung disease or pulmonary arterial hypertension, different videocapillaroscopy pattern, limited or diffuse skin subset.

Conclusion: The visfatin and adiponectin could play an important role in pathogetic mechanism in pericardial effusion in systemic sclerosis. Futher study are necessary to unravel a role of visfatin and adiponectin as biomarkers of SSc pathology.


Disclosure: A. Chialà, None; C. Rotondo, None; M. G. Anelli, None; E. Praino, None; L. Cantarini, None; C. Scioscia, None; M. Giannini, None; G. Lapadula, None; F. Iannone, None.

To cite this abstract in AMA style:

Chialà A, Rotondo C, Anelli MG, Praino E, Cantarini L, Scioscia C, Giannini M, Lapadula G, Iannone F. Evaluation of Serum Levels of Adipokines and Interleukines in Pericardial Effusion Related to Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-serum-levels-of-adipokines-and-interleukines-in-pericardial-effusion-related-to-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-serum-levels-of-adipokines-and-interleukines-in-pericardial-effusion-related-to-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology